const L123 = [
  {
    "id": 1,
    "category": "Cephalosporins: Clinical Use",
    "questionText": "A 62-year-old male is scheduled for a coronary artery bypass graft (CABG). He has no known drug allergies. To prevent post-operative infection from common skin flora like MSSA, which of the following antibiotics is the preferred agent for surgical prophylaxis?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is correct. Cefazolin is a first-generation cephalosporin with excellent activity against MSSA and S. pyogenes, making it a preferred agent for surgical prophylaxis."},
      {"text": "Ceftriaxone", "explanation": "This is incorrect. Ceftriaxone is a third-generation agent with less potent activity against MSSA than first-generation agents."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. Ceftazidime is a third-generation agent with a focus on Pseudomonas and has poor gram-positive activity."},
      {"text": "Cefoxitin", "explanation": "This is incorrect. Cefoxitin is a second-generation cephamycin used for its anaerobic coverage (e.g., B. fragilis) in abdominal surgery, not typically for cardiothoracic surgery."},
      {"text": "Ceftaroline", "explanation": "This is incorrect. Ceftaroline is an advanced-generation agent reserved for treating active MRSA infections, not for routine surgical prophylaxis."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L123_page-0017.jpg"
  },
  {
    "id": 2,
    "category": "Cephalosporins: Pharmacokinetics",
    "questionText": "A 5-day-old neonate presents with fever, lethargy, and a bulging fontanelle. Sepsis and meningitis are suspected. The team initiates ampicillin and a third-generation cephalosporin. Which agent is preferred in this specific patient to avoid the risk of kernicterus?",
    "options": [
      {"text": "Ceftriaxone", "explanation": "This is incorrect. Ceftriaxone is highly protein-bound and can displace bilirubin from albumin, leading to hyperbilirubinemia and a risk of kernicterus in neonates."},
      {"text": "Cefotaxime", "explanation": "This is correct. Cefotaxime is preferred in neonates because it does not displace bilirubin from plasma proteins and therefore does not carry the same risk of kernicterus as ceftriaxone."},
      {"text": "Cefazolin", "explanation": "This is incorrect. Cefazolin is a first-generation agent and has poor penetration into the CSF, making it unsuitable for meningitis."},
      {"text": "Cefepime", "explanation": "This is incorrect. While Cefepime penetrates the CSF, Cefotaxime is specifically noted as preferred over Ceftriaxone for this exact reason in neonates."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. Ceftazidime has poor gram-positive coverage and is not the empirical choice for neonatal meningitis."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0019.jpg"
  },
  {
    "id": 3,
    "category": "Cephalosporins: Adverse Effects",
    "questionText": "A 68-year-old male with a history of alcohol use disorder is being treated with Cefotetan for a polymicrobial intra-abdominal infection. The patient consumes alcohol against medical advice and develops flushing, nausea, and vomiting. This reaction is due to the drug's inhibition of which enzyme?",
    "options": [
      {"text": "Dehydropeptidase I", "explanation": "This is incorrect. Dehydropeptidase I is inhibited by cilastatin to protect imipenem."},
      {"text": "Beta-lactamase", "explanation": "This is incorrect. This is a bacterial resistance enzyme, not the target for this patient's adverse effect."},
      {"text": "Aldehyde dehydrogenase", "explanation": "This is correct. Cefotetan has a side chain that inhibits aldehyde dehydrogenase, leading to an accumulation of aldehyde and a disulfiram-like reaction when alcohol is consumed."},
      {"text": "Transpeptidase", "explanation": "This is incorrect. This is the bacterial target (PBP) of all beta-lactam antibiotics."},
      {"text": "Transglycosylase", "explanation": "This is incorrect. This is the bacterial target of vancomycin."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0045.jpg"
  },
  {
    "id": 4,
    "category": "Advanced Cephalosporins: MOA/SOA",
    "questionText": "A 55-year-old diabetic patient presents with a severe, complicated skin and soft tissue infection. Cultures grow MRSA. The physician starts an IV beta-lactam antibiotic that is uniquely able to bind to PBP2a. Which drug was most likely administered?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. Cefazolin is a first-generation cephalosporin and is not effective against MRSA."},
      {"text": "Cefepime", "explanation": "This is incorrect. Cefepime is a fourth-generation agent and is not effective against MRSA."},
      {"text": "Ceftriaxone", "explanation": "This is incorrect. Ceftriaxone is a third-generation agent and is not effective against MRSA."},
      {"text": "Ceftaroline", "explanation": "This is correct. Ceftaroline is an advanced-generation cephalosporin and is the only beta-lactam with high affinity for PBP2a, the altered PBP that confers methicillin resistance."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. Ceftazidime has poor gram-positive activity and is not effective against MRSA."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0014.jpg"
  },
  {
    "id": 5,
    "category": "Carbapenems: Pharmacokinetics",
    "questionText": "A 70-year-old patient with hospital-acquired pneumonia is started on Imipenem-Cilastatin. The purpose of co-administering cilastatin is to prevent imipenem's inactivation by which of the following?",
    "options": [
      {"text": "Bacterial beta-lactamases", "explanation": "This is incorrect. Cilastatin is not a beta-lactamase inhibitor; relebactam and vaborbactam serve that role for carbapenems."},
      {"text": "Pulmonary surfactant", "explanation": "This is incorrect. Daptomycin is inactivated by pulmonary surfactant, not imipenem."},
      {"text": "Dehydropeptidase I in the renal tubules", "explanation": "This is correct. Cilastatin inhibits dehydropeptidase I, an enzyme in the brush border of the proximal renal tubules that inactivates imipenem."},
      {"text": "Plasma protein binding", "explanation": "This is incorrect. Cilastatin does not function by altering plasma protein binding."},
      {"text": "Biliary excretion", "explanation": "This is incorrect. Cilastatin works in the kidney, not the biliary system."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0022.jpg"
  },
  {
    "id": 6,
    "category": "Carbapenems: Adverse Effects",
    "questionText": "A 75-year-old male with severe renal insufficiency (CrCl < 20 mL/min) is being treated with Imipenem-Cilastatin for a complicated intra-abdominal infection. The patient's dose is not properly adjusted. He is at an increased risk for developing which of the following neurologic adverse effects?",
    "options": [
      {"text": "Ototoxicity", "explanation": "This is incorrect. Ototoxicity is a rare side effect associated with vancomycin and aminoglycosides."},
      {"text": "Seizures", "explanation": "This is correct. Imipenem carries the greatest risk of seizures among the carbapenems, and this risk is significantly increased in patients with renal insufficiency if the dose is not adjusted."},
      {"text": "Kernicterus", "explanation": "This is incorrect. Kernicterus is a risk for neonates treated with ceftriaxone."},
      {"text": "Eosinophilic pneumonia", "explanation": "This is incorrect. This is a rare, delayed adverse effect associated with daptomycin."},
      {"text": "Peripheral neuropathy", "explanation": "This is incorrect. While possible, seizures are the most significant and well-known neurologic complication of high-dose imipenem in renal failure."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0025.jpg"
  },
  {
    "id": 7,
    "category": "Monobactams: Clinical Use",
    "questionText": "A 30-year-old female with a history of anaphylaxis to penicillin presents with a complicated urinary tract infection. Cultures grow *Pseudomonas aeruginosa*. Which of the following beta-lactam antibiotics has a unique structure that confers a very low immunogenic potential and is generally safe to use in this patient?",
    "options": [
      {"text": "Meropenem", "explanation": "This is incorrect. Carbapenems have some cross-reactivity with penicillins and would be used with extreme caution, if at all, after anaphylaxis."},
      {"text": "Cefepime", "explanation": "This is incorrect. Cephalosporins have a low but real cross-reactivity with penicillins, and would be avoided in a patient with a history of anaphylaxis."},
      {"text": "Aztreonam", "explanation": "This is correct. Aztreonam is a monobactam with a structure that is not cross-reactive with other beta-lactams, giving it a low immunogenic potential. It is active against gram-negative aerobes, including *P. aeruginosa*."},
      {"text": "Ceftaroline", "explanation": "This is incorrect. Ceftaroline is a cephalosporin and carries a risk of cross-reactivity with penicillin."},
      {"text": "Imipenem-Cilastatin", "explanation": "This is incorrect. Carbapenems have some cross-reactivity with penicillins."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0028.jpg"
  },
  {
    "id": 8,
    "category": "Vancomycin: Mechanism of Action",
    "questionText": "A patient is being treated with vancomycin for an MRSA infection. This antibiotic inhibits bacterial cell wall synthesis by binding to which specific target, thereby blocking the transglycosylase reaction?",
    "options": [
      {"text": "Penicillin-binding protein 2a (PBP2a)", "explanation": "This is incorrect. PBP2a is the target of ceftaroline; it is the mechanism of MRSA *resistance* to most beta-lactams."},
      {"text": "D-Ala-D-Ala terminus of the precursor unit", "explanation": "This is correct. Vancomycin, a glycopeptide, binds to the D-alanyl-D-alanine terminus of the cell wall precursor, which inhibits the transglycosylase (polymerization) reaction."},
      {"text": "The 30S ribosomal subunit", "explanation": "This is incorrect. This is the target of tetracyclines and aminoglycosides."},
      {"text": "DNA gyrase (topoisomerase II)", "explanation": "This is incorrect. This is the target of fluoroquinolones."},
      {"text": "The bacterial cell membrane via calcium", "explanation": "This is incorrect. This describes the mechanism of action for daptomycin."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0031.jpg"
  },
  {
    "id": 9,
    "category": "Vancomycin: Adverse Effects",
    "questionText": "A 58-year-old man with MRSA endocarditis is receiving IV vancomycin. 20 minutes into the infusion, he develops an erythematous rash and flushing over his face, neck, and upper torso, accompanied by pruritis. This reaction is most likely a non-immune anaphylactoid reaction known as 'red man syndrome'. What is the most appropriate management?",
    "options": [
      {"text": "Stop the infusion immediately and permanently label the patient as 'allergic'.", "explanation": "This is incorrect. This is a rate-related infusion reaction, not a true (immune) allergy, and the drug can often be continued."},
      {"text": "Slow the infusion rate and administer an antihistamine.", "explanation": "This is correct. 'Red man syndrome' is a non-immune reaction caused by rapid infusion. Management involves slowing the infusion and treating symptoms with antihistamines."},
      {"text": "Administer intramuscular epinephrine immediately.", "explanation": "This is incorrect. Epinephrine is the treatment for true anaphylaxis, which this is not."},
      {"text": "Switch to oral vancomycin, as this route does not cause the reaction.", "explanation": "This is incorrect. Oral vancomycin is not absorbed and cannot be used to treat a systemic infection like endocarditis."},
      {"text": "Check serum creatine kinase (CK) levels.", "explanation": "This is incorrect. CK levels are monitored for daptomycin-induced myopathy, not this reaction."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0035.jpg"
  },
  {
    "id": 10,
    "category": "Vancomycin: Resistance",
    "questionText": "A patient has an infection with Vancomycin-Resistant Enterococcus (VRE). This high-level resistance is most commonly due to the acquisition of *vanA* or *vanB* genes, which modify the vancomycin binding target from D-Ala-D-Ala to which of the following?",
    "options": [
      {"text": "D-Ala-D-Lactate", "explanation": "This is correct. The *vanA* and *vanB* genes express enzymes that substitute D-lactate for D-alanine, creating a D-Ala-D-Lactate terminus that has a 1000-fold reduced affinity for vancomycin."},
      {"text": "D-Ala-D-Serine", "explanation": "This is incorrect. The key substitution conferring high-level resistance is D-Lactate."},
      {"text": "A thickened cell wall with extra D-Ala-D-Ala", "explanation": "This is incorrect. This describes the mechanism for vancomycin-intermediate *S. aureus* (VISA), not high-level VRE resistance."},
      {"text": "An altered PBP2a", "explanation": "This is incorrect. This is the mechanism of methicillin resistance in MRSA."},
      {"text": "Efflux pumps that remove vancomycin", "explanation": "This is incorrect. The primary mechanism is target site modification."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L123_page-0032.jpg"
  },
  {
    "id": 11,
    "category": "Daptomycin: Mechanism of Action",
    "questionText": "A patient with a VRE bloodstream infection is treated with daptomycin. This antibiotic exerts its bactericidal effect by binding to the bacterial plasma membrane in a calcium-dependent manner, leading to which of the following downstream events?",
    "options": [
      {"text": "Inhibition of transpeptidase", "explanation": "This is incorrect. This is the mechanism of beta-lactam antibiotics."},
      {"text": "Inhibition of transglycosylase", "explanation": "This is incorrect. This is the mechanism of vancomycin."},
      {"text": "Inhibition of DNA gyrase", "explanation": "This is incorrect. This is the mechanism of fluoroquinolones."},
      {"text": "Membrane depolarization and potassium efflux", "explanation": "This is correct. Daptomycin's Ca2+-dependent insertion forms a pore, causing rapid potassium efflux, membrane depolarization, and subsequent arrest of DNA, RNA, and protein synthesis."},
      {"text": "Binding to the 50S ribosomal subunit", "explanation": "This is incorrect. This is the mechanism of macrolides, clindamycin, and linezolid."}
    ],
    "correctAnswerIndex": 4,
    "slideImagePath": "images/L123_page-0038.jpg"
  },
  {
    "id": 12,
    "category": "Daptomycin: Clinical Use",
    "questionText": "A 68-year-old man in the ICU develops a ventilator-associated pneumonia (VAP). Cultures from his bronchoalveolar lavage grow MRSA. The physician considers starting daptomycin. Why is daptomycin contraindicated for this specific infection?",
    "options": [
      {"text": "It is inactivated by pulmonary surfactants.", "explanation": "This is correct. Daptomycin is ineffective for pneumonia because it is bound and inactivated by pulmonary surfactants in the lungs."},
      {"text": "It has no activity against MRSA.", "explanation": "This is incorrect. Daptomycin has excellent activity against MRSA."},
      {"text": "It cannot be given IV.", "explanation": "This is incorrect. Daptomycin is an IV-only medication for systemic infections."},
      {"text": "It causes severe seizures in ICU patients.", "explanation": "This is incorrect. Seizures are a known risk of imipenem, not daptomycin."},
      {"text": "It only has activity against gram-negative bacteria.", "explanation": "This is incorrect. Daptomycin has activity against gram-positive bacteria *only*."}
    ],
    "correctAnswerIndex": 0,
    "slideImagePath": "images/L123_page-0039.jpg"
  },
  {
    "id": 13,
    "category": "Daptomycin: Adverse Effects",
    "questionText": "A 66-year-old male with a history of hyperlipidemia treated with atorvastatin is started on daptomycin for a complicated MRSA skin infection. This drug combination requires regular monitoring of which lab value due to the risk of an additive toxicity?",
    "options": [
      {"text": "Serum creatinine", "explanation": "This is incorrect. This is the primary monitoring for vancomycin-associated nephrotoxicity."},
      {"text": "Alanine aminotransferase (ALT)", "explanation": "This is incorrect. While statins can affect the liver, the key additive toxicity with daptomycin is not hepatic."},
      {"text": "Prothrombin time (PT)", "explanation": "This is incorrect. This would be monitored for Cefotetan or warfarin therapy."},
      {"text": "Serum potassium", "explanation": "This is incorrect. While daptomycin causes potassium *efflux* from bacteria, it doesn't typically cause hypo- or hyperkalemia in the patient."},
      {"text": "Creatine kinase (CK)", "explanation": "This is correct. Daptomycin can cause myopathy, and HMG-CoA reductase inhibitors (statins) also carry this risk. The combination can lead to additive muscle toxicity, which is monitored by checking CK levels."}
    ],
    "correctAnswerIndex": 4,
    "slideImagePath": "images/L123_page-0040.jpg"
  },
  {
    "id": 14,
    "category": "Cephalosporins: Clinical Use",
    "questionText": "A 22-year-old male presents to an urgent care clinic with a 2-day history of purulent urethral discharge. A gram stain is performed, and he is diagnosed with uncomplicated gonorrhea. According to CDC recommendations, what is the single-injection IM treatment of choice for this infection?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. Cefazolin does not have reliable activity against *N. gonorrhoeae*."},
      {"text": "Ceftriaxone", "explanation": "This is correct. A single IM injection of ceftriaxone is the only CDC-recommended treatment for uncomplicated gonorrhea, due to its high activity and widespread resistance to other agents."},
      {"text": "Cefepime", "explanation": "This is incorrect. Cefepime is not approved for use in treating gonorrhea."},
      {"text": "Ceftaroline", "explanation": "This is incorrect. Ceftaroline is not the recommended agent for gonorrhea."},
      {"text": "Cefoxitin", "explanation": "This is incorrect. While older cephalosporins were used, ceftriaxone is the current standard of care."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0018.jpg"
  },
  {
    "id": 15,
    "category": "Carbapenems: Spectrum of Activity",
    "questionText": "A patient in the ICU has a severe infection caused by an ESBL-producing *Klebsiella pneumoniae*. This organism is resistant to all penicillins and cephalosporins. Which of the following antibiotics is generally considered a treatment of choice for this type of resistant organism?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. ESBLs hydrolyze first-generation cephalosporins."},
      {"text": "Aztreonam", "explanation": "This is incorrect. ESBLs hydrolyze and confer resistance to aztreonam."},
      {"text": "Vancomycin", "explanation": "This is incorrect. Vancomycin has no activity against gram-negative bacteria like *Klebsiella*."},
      {"text": "Meropenem", "explanation": "This is correct. Carbapenems (like meropenem and imipenem) are stable to ESBLs and are considered the treatment of choice for serious infections caused by ESBL-expressing Enterobacterales."},
      {"text": "Daptomycin", "explanation": "This is incorrect. Daptomycin has no activity against gram-negative bacteria."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0024.jpg"
  },
  {
    "id": 16,
    "category": "Cephalosporins: Spectrum of Activity",
    "questionText": "A 4-year-old child presents with otitis media and sinusitis. The pediatrician suspects a bacterial infection, likely caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, or *Moraxella catarrhalis*. Which of the following cephalosporin generations provides reliable coverage against all three of these common respiratory pathogens?",
    "options": [
      {"text": "First-generation (e.g., Cephalexin)", "explanation": "This is incorrect. First-generation agents have poor activity against *H. influenzae* and *M. catarrhalis*."},
      {"text": "Second-generation (e.g., Cefuroxime)", "explanation": "This is correct. Second-generation cephalosporins were designed to expand gram-negative coverage to include respiratory pathogens like *H. influenzae* and *M. catarrhalis*, while retaining G+ coverage for *S. pneumoniae*."},
      {"text": "Cefoxitin (cephamycin subgroup)", "explanation": "This is incorrect. While technically a 2nd-gen, the cephamycin subgroup's unique feature is *B. fragilis* coverage, not necessarily enhanced respiratory coverage."},
      {"text": "Ceftazidime (third-generation)", "explanation": "This is incorrect. Ceftazidime has poor gram-positive activity and would not be a good choice for *S. pneumoniae*."},
      {"text": "Aztreonam", "explanation": "This is incorrect. Aztreonam has no activity against gram-positive organisms like *S. pneumoniae*."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0011.jpg"
  },
  {
    "id": 17,
    "category": "Carbapenems: Spectrum of Activity",
    "questionText": "A 50-year-old patient with diabetes has a severe polymicrobial diabetic foot infection. The physician needs an antibiotic with a very broad spectrum, covering G+ cocci, G- rods, and anaerobes like *B. fragilis*. Which of the following carbapenems has a narrower spectrum and is known to be *ineffective* against *Pseudomonas aeruginosa*?",
    "options": [
      {"text": "Imipenem", "explanation": "This is incorrect. Imipenem is active against *P. aeruginosa*."},
      {"text": "Meropenem", "explanation": "This is incorrect. Meropenem is active against *P. aeruginosa*."},
      {"text": "Doripenem", "explanation": "This is incorrect. Doripenem is active against *P. aeruginosa*."},
      {"text": "Ertapenem", "explanation": "This is correct. Ertapenem is the exception among carbapenems and is notably *ineffective* against *Pseudomonas aeruginosa* and *Enterococcus* species."},
      {"text": "Meropenem-vaborbactam", "explanation": "This is incorrect. The meropenem component is active against *P. aeruginosa*."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0024.jpg"
  },
  {
    "id": 18,
    "category": "Monobactams: Spectrum of Activity",
    "questionText": "A patient is started on aztreonam. This antibiotic has a narrow spectrum of activity and is *only* effective against which of the following classes of bacteria?",
    "options": [
      {"text": "Gram-positive aerobes", "explanation": "This is incorrect. Aztreonam has no activity against gram-positive bacteria."},
      {"text": "Gram-negative aerobes", "explanation": "This is correct. Aztreonam's spectrum is limited to gram-negative aerobic cocci and bacilli, including *P. aeruginosa*."},
      {"text": "Obligate anaerobes", "explanation": "This is incorrect. Aztreonam has no activity against anaerobes."},
      {"text": "Atypical bacteria", "explanation": "This is incorrect. Like other beta-lactams, aztreonam is not effective against atypical bacteria."},
      {"text": "All of the above", "explanation": "This is incorrect. Aztreonam has a very narrow spectrum."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0028.jpg"
  },
  {
    "id": 19,
    "category": "Cephalosporins: Pharmacokinetics",
    "questionText": "A 70-year-old male with meningitis is being treated with ceftriaxone. He has concomitant severe renal impairment (CrCl 15 mL/min). Why is dose adjustment for ceftriaxone *not* required in this patient?",
    "options": [
      {"text": "It is inactivated by pulmonary surfactant.", "explanation": "This is incorrect. This describes daptomycin and is irrelevant to its elimination."},
      {"text": "It is eliminated primarily via the biliary system.", "explanation": "This is correct. Ceftriaxone is unique among cephalosporins in that it undergoes biliary excretion, so dose adjustment for renal impairment is not required (unless there is also hepatic failure)."},
      {"text": "It is co-administered with cilastatin.", "explanation": "This is incorrect. This applies to imipenem."},
      {"text": "It has a very short half-life.", "explanation": "This is incorrect. Ceftriaxone has a very *long* half-life, but its elimination route (biliary) is the reason dose adjustment isn't needed."},
      {"text": "It binds to PBP2a.", "explanation": "This is incorrect. This describes the mechanism of ceftaroline."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0008.jpg"
  },
  {
    "id": 20,
    "category": "Vancomycin: Clinical Use",
    "questionText": "A 50-year-old patient is diagnosed with severe *Clostridioides difficile* colitis (C. diff). The physician decides to treat with oral vancomycin. Why is the *oral* formulation effective for this condition, whereas the *IV* formulation is not?",
    "options": [
      {"text": "IV vancomycin does not have activity against *C. difficile*.", "explanation": "This is incorrect. Vancomycin has excellent activity against the gram-positive anaerobe *C. difficile*."},
      {"text": "Oral vancomycin is designed to cause 'Red Man Syndrome' in the gut.", "explanation": "This is incorrect. 'Red Man Syndrome' is a systemic infusion reaction."},
      {"text": "Oral vancomycin is poorly absorbed and acts locally in the gut.", "explanation": "This is correct. Oral vancomycin has poor GI absorption, so it remains in the gut lumen where it can kill *C. difficile*. IV vancomycin is used for systemic infections and does not reach high enough concentrations in the gut lumen."},
      {"text": "IV vancomycin is inactivated by gastric acid.", "explanation": "This is incorrect. IV vancomycin is never given orally for systemic effect; its lack of absorption is the key factor."},
      {"text": "Oral vancomycin inhibits PBP2a, while IV vancomycin does not.", "explanation": "This is incorrect. Vancomycin's mechanism (binding D-Ala-D-Ala) is the same regardless of route, and it does not target PBP2a."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0033.jpg"
  },
  {
    "id": 21,
    "category": "Resistance Mechanisms",
    "questionText": "A sputum culture from a patient with VAP grows a gram-negative rod that is resistant to all penicillins and cephalosporins. The lab reports the organism is an *Klebsiella pneumoniae* carbapenemase (KPC) producer. Which of the following antibiotics would also be rendered ineffective by this enzyme?",
    "options": [
      {"text": "Vancomycin", "explanation": "This is incorrect. Vancomycin is not a beta-lactam and is not affected by KPCs; however, it has no G- activity."},
      {"text": "Daptomycin", "explanation": "This is incorrect. Daptomycin is not a beta-lactam and is not affected by KPCs; however, it has no G- activity."},
      {"text": "Meropenem", "explanation": "This is correct. KPCs are Class A beta-lactamases that hydrolyze and confer resistance to penicillins, cephalosporins, and carbapenems (like meropenem)."},
      {"text": "Ceftaroline", "explanation": "This is incorrect. Ceftaroline is a cephalosporin and would already be ineffective."},
      {"text": "Cefiderocol", "explanation": "This is incorrect. Cefiderocol is generally stable against KPCs."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0024.jpg"
  },
  {
    "id": 22,
    "category": "Cephalosporins: Spectrum of Activity",
    "questionText": "A 20-year-old college student is diagnosed with bacterial meningitis. The CSF gram stain shows gram-negative diplococci. Which third-generation cephalosporin is a drug of choice for this infection due to its excellent CSF penetration and high activity against *Neisseria meningitidis*?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. Cefazolin has poor CSF penetration and poor activity against *Neisseria*."},
      {"text": "Cefoxitin", "explanation": "This is incorrect. Cefoxitin has poor CSF penetration."},
      {"text": "Ceftriaxone", "explanation": "This is correct. Ceftriaxone (and cefotaxime) is an agent of choice for meningitis. It achieves high concentrations in inflamed meninges and is highly active against *N. meningitidis*."},
      {"text": "Cephalexin", "explanation": "This is incorrect. This is an oral first-generation agent and is inappropriate for meningitis."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. While Ceftazidime penetrates the CSF, its primary use is for *Pseudomonas*, and it has weaker activity against many other organisms compared to ceftriaxone."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0018.jpg"
  },
  {
    "id": 23,
    "category": "Daptomycin: Adverse Effects",
    "questionText": "A 59-year-old female receiving daptomycin for VRE bacteremia develops a new-onset cough, fever, and dyspnea 3 weeks into therapy. A chest X-ray shows new pulmonary infiltrates. This presentation is concerning for which rare but serious adverse effect of daptomycin?",
    "options": [
      {"text": "Myopathy", "explanation": "This is incorrect. Myopathy presents with muscle pain and weakness, not pulmonary infiltrates."},
      {"text": "Red Man Syndrome", "explanation": "This is incorrect. This is an acute infusion reaction, not a delayed pulmonary syndrome."},
      {"text": "Eosinophilic pneumonia", "explanation": "This is correct. Daptomycin can cause a rare, delayed-onset eosinophilic pneumonia (typically 10 days to 4 weeks after starting) presenting with fever, dyspnea, and infiltrates."},
      {"text": "Kernicterus", "explanation": "This is incorrect. This is a neonatal risk with ceftriaxone."},
      {"text": "Nephrotoxicity", "explanation": "This is incorrect. While a possible side effect, it does not present with pulmonary infiltrates. This presentation is classic for eosinophilic pneumonia."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0040.jpg"
  },
  {
    "id": 24,
    "category": "Cephalosporins: Adverse Effects",
    "questionText": "A 2-week-old neonate with sepsis is being treated in the NICU. The resident orders IV ceftriaxone. The pharmacist calls to intervene, warning that ceftriaxone is contraindicated in this patient because it can form a fatal precipitate with what commonly infused IV solution?",
    "options": [
      {"text": "Sodium chloride 0.9%", "explanation": "This is incorrect. Ceftriaxone is compatible with normal saline."},
      {"text": "Dextrose 5% in water (D5W)", "explanation": "This is incorrect. Ceftriaxone is compatible with D5W."},
      {"text": "Calcium-containing solutions (e.g., TPN, Ringer's lactate)", "explanation": "This is correct. Ceftriaxone can form a precipitate with calcium, which can deposit in the lungs and kidneys, causing damage. This is a specific contraindication in neonates."},
      {"text": "Potassium chloride", "explanation": "This is incorrect. While electrolyte abnormalities are a concern, the specific fatal precipitate is with calcium."},
      {"text": "Magnesium sulfate", "explanation": "This is incorrect. The specific contraindication is with calcium-containing solutions."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0019.jpg"
  },
  {
    "id": 25,
    "category": "Vancomycin: Spectrum of Activity",
    "questionText": "A 45-year-old man with no known drug allergies has a severe MSSA (Methicillin-Susceptible *S. aureus*) bloodstream infection. The team is deciding between vancomycin and nafcillin. Why is nafcillin (a penicillinase-resistant penicillin) preferred over vancomycin for this specific infection?",
    "options": [
      {"text": "Vancomycin has no activity against MSSA.", "explanation": "This is incorrect. Vancomycin is active against MSSA."},
      {"text": "Nafcillin has better activity against MSSA than vancomycin.", "explanation": "This is correct. For MSSA infections, penicillinase-resistant penicillins like nafcillin are preferred because they have better activity (are more rapidly bactericidal) than vancomycin."},
      {"text": "Vancomycin causes a disulfiram-like reaction.", "explanation": "This is incorrect. This is associated with cefotetan, not vancomycin."},
      {"text": "Nafcillin can be given orally.", "explanation": "This is incorrect. Nafcillin is an IV-only agent; dicloxacillin is the oral equivalent."},
      {"text": "Vancomycin is inactivated by pulmonary surfactant.", "explanation": "This is incorrect. This describes daptomycin."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0032.jpg"
  },
  {
    "id": 26,
    "category": "Advanced Cephalosporins: MOA/SOA",
    "questionText": "A patient has a complicated UTI with a multidrug-resistant (MDR) *P. aeruginosa*. The physician prescribes Cefiderocol. This antibiotic has a unique mechanism of entry into gram-negative bacteria by acting as a siderophore and binding to which of the following?",
    "options": [
      {"text": "Bacterial beta-lactamases", "explanation": "This is incorrect. This is what the drug avoids or overcomes, it's not its entry mechanism."},
      {"text": "Extracellular free iron", "explanation": "This is correct. Cefiderocol is a siderophore that chelates extracellular free iron, which allows it to be actively transported across the outer membrane of GNBs via their iron transport systems."},
      {"text": "Penicillin-binding proteins on the outer membrane", "explanation": "This is incorrect. PBPs are the target, but they are located in the periplasmic space, not the outer membrane, and are not part of the entry mechanism."},
      {"text": "D-Ala-D-Lactate", "explanation": "This is incorrect. This is the resistance mechanism for VRE."},
      {"text": "The cytoplasmic membrane", "explanation": "This is incorrect. This is the target of daptomycin."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0014.jpg"
  },
  {
    "id": 27,
    "category": "Resistance Mechanisms",
    "questionText": "A 52-year-old female has a severe skin infection. Cultures grow *S. aureus* that is resistant to nafcillin. This resistance is due to an altered PBP2a. She is started on vancomycin, but cultures show intermediate resistance (VISA). This *intermediate* resistance to vancomycin is due to which mechanism?",
    "options": [
      {"text": "Production of a KPC enzyme.", "explanation": "This is incorrect. KPCs are beta-lactamases found in gram-negative bacteria."},
      {"text": "Modification of the binding target to D-Ala-D-Lactate.", "explanation": "This is incorrect. This describes high-level resistance (VRSA), not intermediate resistance (VISA)."},
      {"text": "Formation of an abnormally thick cell wall that traps vancomycin.", "explanation": "This is correct. VISA is characterized by an altered cell wall metabolism that leads to a thick cell wall with increased D-Ala-D-Ala residues, which 'trap' or sequester the drug."},
      {"text": "Inactivation of vancomycin by pulmonary surfactant.", "explanation": "This is incorrect. This is a property of daptomycin, not a bacterial resistance mechanism."},
      {"text": "A mutation in the iron transport system.", "explanation": "This is incorrect. This would be a resistance mechanism to cefiderocol."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0032.jpg"
  },
  {
    "id": 28,
    "category": "Monobactams: Clinical Use",
    "questionText": "A 19-year-old patient with cystic fibrosis has a chronic *P. aeruginosa* lung infection. In addition to systemic antibiotics, which of the following beta-lactams is available as an oral inhalation formulation specifically for this indication?",
    "options": [
      {"text": "Meropenem", "explanation": "This is incorrect. Meropenem is IV only."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. Ceftazidime is IV/IM."},
      {"text": "Cefepime", "explanation": "This is incorrect. Cefepime is IV/IM."},
      {"text": "Vancomycin", "explanation": "This is incorrect. Vancomycin is not used for *P. aeruginosa* and its inhaled use is not standard."},
      {"text": "Aztreonam", "explanation": "This is correct. Aztreonam is available as an inhalation solution for the treatment of *P. aeruginosa* lung infections in patients with cystic fibrosis."}
    ],
    "correctAnswerIndex": 4,
    "slideImagePath": "images/L123_page-0028.jpg"
  },
  {
    "id": 29,
    "category": "Carbapenem Combos: MOA/SOA",
    "questionText": "A patient has a complicated intra-abdominal infection caused by a KPC-producing *E. coli*. The physician prescribes meropenem-vaborbactam. What is the specific role of vaborbactam in this combination?",
    "options": [
      {"text": "It inhibits renal dehydropeptidase I.", "explanation": "This is incorrect. That is the role of cilastatin with imipenem."},
      {"text": "It binds to PBP2a to treat MRSA.", "explanation": "This is incorrect. This combo is for G- infections, and this mechanism describes ceftaroline."},
      {"text": "It binds to extracellular iron.", "explanation": "This is incorrect. This is the mechanism of cefiderocol."},
      {"text": "It inhibits the KPC beta-lactamase enzyme.", "explanation": "This is correct. Vaborbactam is a beta-lactamase inhibitor that inhibits Ambler class A beta-lactamases, including KPCs, thereby restoring meropenem's activity against KPC-producing organisms."},
      {"text": "It depolarizes the bacterial cell membrane.", "explanation": "This is incorrect. This is the mechanism of daptomycin."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0026.jpg"
  },
  {
    "id": 30,
    "category": "Cephalosporins: Spectrum of Activity",
    "questionText": "A patient presents with a severe community-acquired pneumonia. Cultures grow *Streptococcus pneumoniae* that is found to be penicillin-resistant. Which advanced-generation cephalosporin would be an effective treatment because it retains activity against this organism, in addition to having activity against MRSA?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. Cefazolin would not be effective against penicillin-resistant *S. pneumoniae*."},
      {"text": "Ceftazidime", "explanation": "This is incorrect. Ceftazidime has poor activity against *S. pneumoniae*."},
      {"text": "Cefiderocol", "explanation": "This is incorrect. Cefiderocol has no activity against gram-positive bacteria."},
      {"text": "Ceftaroline", "explanation": "This is correct. Ceftaroline has broad gram-positive activity, including against penicillin-resistant *S. pneumoniae* and MRSA."},
      {"text": "Cefoxitin", "explanation": "This is incorrect. Second-generation agents are not the preferred treatment for penicillin-resistant *S. pneumoniae*."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0014.jpg"
  },
  {
    "id": 31,
    "category": "Resistance Mechanisms",
    "questionText": "A patient has an infection with *Enterococcus faecalis*. This organism, along with *Listeria monocytogenes*, demonstrates intrinsic resistance to which entire class of antibiotics due to low-affinity PBPs?",
    "options": [
      {"text": "Penicillins", "explanation": "This is incorrect. Penicillins (like ampicillin) are active against *Enterococcus* and *Listeria*."},
      {"text": "Carbapenems", "explanation": "This is incorrect. Carbapenems (except ertapenem) are active against *E. faecalis* and *Listeria*."},
      {"text": "Cephalosporins", "explanation": "This is correct. *Enterococcus* species and *Listeria monocytogenes* are intrinsically resistant to all cephalosporins due to having low-affinity PBPs."},
      {"text": "Glycopeptides (Vancomycin)", "explanation": "This is incorrect. Vancomycin is active against *Enterococcus* (unless VRE) and *Listeria*."},
      {"text": "Lipopeptides (Daptomycin)", "explanation": "This is incorrect. Daptomycin is active against *Enterococcus* and *Listeria*."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0016.jpg"
  },
  {
    "id": 32,
    "category": "Pharmacokinetics/Pharmacodynamics",
    "questionText": "A pharmacist is dosing vancomycin for a patient with MRSA bacteremia. To maximize efficacy and minimize nephrotoxicity, the dosing is adjusted to achieve a target 24-hour AUC/MIC ratio of 400-600. This PK/PD profile is best described as:",
    "options": [
      {"text": "Concentration-dependent killing", "explanation": "This is incorrect. While related, the key parameter is the *area under the curve* relative to the MIC, not just the peak concentration."},
      {"text": "Time-dependent killing (T>MIC)", "explanation": "This is incorrect. T>MIC is the primary driver for beta-lactams, not vancomycin, although T>MIC is also a parameter for vanco."},
      {"text": "Post-antibiotic effect (PAE)", "explanation": "This is incorrect. While vancomycin has a short PAE, the dosing target is the AUC/MIC ratio."},
      {"text": "AUC/MIC dependent killing", "explanation": "This is correct. The clinical efficacy of vancomycin correlates with the 24-hour AUC/MIC ratio, and targeting this value (e.g., 400-600 for MRSA) is the modern standard of care."},
      {"text": "Inhibition of a renal enzyme", "explanation": "This is incorrect. This describes the action of cilastatin, not a PK/PD parameter."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0030.jpg"
  },
  {
    "id": 33,
    "category": "Cephalosporins: Spectrum of Activity",
    "questionText": "A patient has a ruptured appendix, and a polymicrobial infection is suspected. The surgeon wants to provide prophylactic coverage against gram-negative rods and the common obligate anaerobe, *Bacteroides fragilis*. Which of the following cephalosporins belongs to the cephamycin subgroup and is specifically known for its activity against *B. fragilis*?",
    "options": [
      {"text": "Cefazolin", "explanation": "This is incorrect. First-generation cephalosporins have no significant anaerobic activity."},
      {"text": "Cefuroxime", "explanation": "This is incorrect. Cefuroxime is a second-generation agent but is not in the cephamycin subgroup and lacks reliable *B. fragilis* coverage."},
      {"text": "Cefoxitin", "explanation": "This is correct. Cefoxitin is a cephamycin (a 2nd-gen subgroup) and has activity against the anaerobe *Bacteroides fragilis*, making it useful for abdominal/pelvic infections."},
      {"text": "Ceftriaxone", "explanation": "This is incorrect. Third-generation agents (except ceftolozane-tazobactam) generally lack activity against *B. fragilis*."},
      {"text": "Cefepime", "explanation": "This is incorrect. Fourth-generation agents lack reliable activity against *B. fragilis*."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0011.jpg"
  },
  {
    "id": 34,
    "category": "Daptomycin: Spectrum of Activity",
    "questionText": "A patient has a complex skin infection that is culture-positive for VRE (*Enterococcus faecium*) and VRSA (*S. aureus*). Vancomycin is not an option. Which of the following antibiotics is a cyclic lipopeptide that is bactericidal against *both* of these resistant gram-positive organisms?",
    "options": [
      {"text": "Ceftaroline", "explanation": "This is incorrect. Ceftaroline is active against MRSA but is *not* active against *Enterococcus* species."},
      {"text": "Meropenem", "explanation": "This is incorrect. Meropenem is not active against MRSA or *E. faecium*."},
      {"text": "Aztreonam", "explanation": "This is incorrect. Aztreonam has no gram-positive activity."},
      {"text": "Daptomycin", "explanation": "This is correct. Daptomycin is a cyclic lipopeptide that is active against all gram-positive pathogens, including vancomycin-resistant strains like VRE and VRSA."},
      {"text": "Cefiderocol", "explanation": "This is incorrect. Cefiderocol has no gram-positive activity."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0039.jpg"
  },
  {
    "id": 35,
    "category": "Vancomycin: Adverse Effects",
    "questionText": "A 72-year-old female is receiving IV vancomycin for MRSA pneumonia. Her other medications include furosemide and an aminoglycoside. This combination of drugs puts her at a significantly increased risk for which of the following toxicities?",
    "options": [
      {"text": "Myopathy", "explanation": "This is incorrect. This is the key toxicity of daptomycin, especially with statins."},
      {"text": "Seizures", "explanation": "This is incorrect. This is the key toxicity of imipenem, especially in renal failure."},
      {"text": "Nephrotoxicity", "explanation": "This is correct. Vancomycin carries a risk of nephrotoxicity, which is increased when co-administered with other nephrotoxic drugs like aminoglycosides and loop diuretics (furosemide)."},
      {"text": "Biliary sludge", "explanation": "This is incorrect. This is a risk associated with ceftriaxone."},
      {"text": "Disulfiram-like reaction", "explanation": "This is incorrect. This is a risk associated with cefotetan."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0034.jpg"
  },
  {
    "id": 36,
    "category": "Cephalosporins: Spectrum of Activity",
    "questionText": "A 65-year-old patient in the ICU has a suspected *Pseudomonas aeruginosa* infection. Which of the following third-generation cephalosporins is known for its anti-pseudomonal activity?",
    "options": [
      {"text": "Ceftriaxone", "explanation": "This is incorrect. Ceftriaxone has poor activity against *P. aeruginosa*."},
      {"text": "Cefotaxime", "explanation": "This is incorrect. Cefotaxime has poor activity against *P. aeruginosa*."},
      {"text": "Cefazolin", "explanation": "This is incorrect. First-generation agents have no activity against *P. aeruginosa*."},
      {"text": "Ceftazidime", "explanation": "This is correct. Ceftazidime is a third-generation cephalosporin specifically used for its activity against *P. aeruginosa*."},
      {"text": "Cephalexin", "explanation": "This is incorrect. This is an oral first-generation agent with no *P. aeruginosa* activity."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0012.jpg"
  },
  {
    "id": 37,
    "category": "Resistance Mechanisms",
    "questionText": "A patient has an infection with *Enterobacter*. The physician starts a third-generation cephalosporin. The infection initially improves, but then the patient decompensates. Repeat cultures show the *Enterobacter* is now resistant. This organism is known to possess an inducible, chromosomally-encoded beta-lactamase. This type of resistance is characteristic of which enzyme?",
    "options": [
      {"text": "KPC (Klebsiella pneumoniae carbapenemase)", "explanation": "This is incorrect. KPCs are typically plasmid-encoded and confer resistance to carbapenems."},
      {"text": "ESBL (Extended-spectrum beta-lactamase)", "explanation": "This is incorrect. ESBLs are typically plasmid-encoded and constitutively expressed."},
      {"text": "AmpC beta-lactamase", "explanation": "This is correct. AmpC beta-lactamases are chromosomally-encoded and can be *inducible* during therapy, especially with third-generation cephalosporins. *Enterobacter* is a classic AmpC-producing organism."},
      {"text": "VanA gene cluster", "explanation": "This is incorrect. This confers vancomycin resistance in gram-positive bacteria."},
      {"text": "PBP2a", "explanation": "This is incorrect. This is the mechanism of methicillin resistance in *S. aureus*."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0015.jpg"
  },
  {
    "id": 38,
    "category": "Pharmacology: General Principles",
    "questionText": "A 25-year-old patient is diagnosed with community-acquired pneumonia. The physician suspects an 'atypical' pathogen like *Mycoplasma pneumoniae*. Why are all beta-lactam antibiotics, including cephalosporins, carbapenem, and aztreonam, ineffective against this organism?",
    "options": [
      {"text": "*Mycoplasma* is an obligate intracellular pathogen.", "explanation": "This is incorrect. This describes *Chlamydia* and *Legionella*. While beta-lactams are also ineffective against them, the reason for *Mycoplasma* is different."},
      {"text": "*Mycoplasma* produces KPC enzymes.", "explanation": "This is incorrect. KPCs are found in gram-negative bacteria."},
      {"text": "*Mycoplasma* lacks a peptidoglycan cell wall.", "explanation": "This is correct. Atypical bacteria like *Mycoplasma pneumoniae* lack a peptidoglycan cell wall, which is the target of all beta-lactam and glycopeptide antibiotics."},
      {"text": "*Mycoplasma* modifies its PBP to PBP2a.", "explanation": "This is incorrect. This is the MRSA resistance mechanism."},
      {"text": "*Mycoplasma* is only susceptible to Cefiderocol.", "explanation": "This is incorrect. Cefiderocol is for gram-negative bacteria."}
    ],
    "correctAnswerIndex": 2,
    "slideImagePath": "images/L123_page-0010.jpg"
  },
  {
    "id": 39,
    "category": "Monobactams: Cross-Reactivity",
    "questionText": "A 50-year-old patient with a penicillin allergy (anaphylaxis) is safely treated with aztreonam for a *E. coli* UTI. Two years later, the patient has a *P. aeruginosa* infection and is given ceftazidime, to which they have an immediate anaphylactic reaction. This cross-reactivity is due to what specific feature?",
    "options": [
      {"text": "Both drugs are hydrolyzed by KPCs.", "explanation": "This is incorrect. This is a resistance mechanism, not a reason for allergic cross-reactivity."},
      {"text": "Both drugs have a similar side chain.", "explanation": "This is correct. Aztreonam has a very low immunogenic potential and does not cross-react with other beta-lactams, *except* for ceftazidime, with which it shares a similar side chain."},
      {"text": "Both drugs are monobactams.", "explanation": "This is incorrect. Ceftazidime is a cephalosporin, not a monobactam."},
      {"text": "Both drugs bind to extracellular iron.", "explanation": "This is incorrect. This describes cefiderocol."},
      {"text": "All beta-lactams have 100% cross-reactivity.", "explanation": "This is incorrect. This is untrue, and aztreonam is the prime example of an exception."}
    ],
    "correctAnswerIndex": 1,
    "slideImagePath": "images/L123_page-0028.jpg"
  },
  {
    "id": 40,
    "category": "Carbapenems: Adverse Effects",
    "questionText": "A 60-year-old male with a history of seizures is hospitalized for a severe infection. The physician wants to use a broad-spectrum carbapenem but is concerned about seizure risk. Which of the following carbapenems is known to have the *greatest* risk for inducing seizures, especially in patients with underlying CNS pathology or renal failure?",
    "options": [
      {"text": "Ertapenem", "explanation": "This is incorrect. While all carbapenems carry some risk, imipenem is associated with the highest risk."},
      {"text": "Meropenem", "explanation": "This is incorrect. Meropenem is known to have a *lower* seizure potential than imipenem."},
      {"text": "Aztreonam", "explanation": "This is incorrect. Aztreonam is a monobactam and is not associated with a high seizure risk."},
      {"text": "Imipenem-cilastatin", "explanation": "This is correct. Imipenem carries the greatest risk of seizures among the carbapenems, particularly at high doses or in patients with renal insufficiency."},
      {"text": "Cefepime", "explanation": "This is incorrect. Cefepime is a cephalosporin. (Note: It also has a risk of neurotoxicity/seizures in renal failure, but the question asks for the carbapenem with the greatest risk)."}
    ],
    "correctAnswerIndex": 3,
    "slideImagePath": "images/L123_page-0025.jpg"
  }
];